Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2015

View Archived Issues

Prediction of tumor response to anti-PD-1 therapy in metastatic melanoma

Roche begins phase I study of RO-6927005 in solid tumors

Merck KGaA commences phase I trial of MSC-2490484A

First patient dosed in phase Ib trial of SYN-004 for the prevention of C. difficile infection

NephroGenex successfully completes QT study of Pyridorin

Warner Chilcott begins phase III study of sarecycline in acne vulgaris

Phase I study of intravenously administered BMS-986168 begins

GABA-A receptor modulation shows promising results for the treatment of autism spectrum disorders

Treatment ongoing in a phase I/II clinical trial of the antitumor RNAi therapeutic TKM-080301

Knight Therapeutics forms product commercialization partnership with NeurAxon

Preclinical investigation of a small-molecule JAK1/TYK2 inhibitor for psoriasis

MMP-3 may be a sex-specific marker of psychiatric disease

Researchers identify novel PS1 mutation involved in early-onset FAD

Shuttle Pharmaceuticals awarded NIH contract for novel radiation sensitizer in GI cancers

4D Pharma advances development of Blautix

United Therapeutics signs agreement with DEKA for development of Remodulin pump system

FDA approves trial protocol for Aethlon's Hemopurifier in patients infected with Ebola virus

Cempra reports results from phase III trial of solithromycin in bacterial pneumonia

Nav1.7 sodium channel blockers described in Amgen patents

Ferrer patents novel orexin OX2 receptor agonists

University of Texas System reports discovery of allosteric proteasome inhibitors

Antabio prepares and tests NDM-1 inhibitors for beta-lactam-resistant infections

Dual specificity protein kinase TTK inhibitors in early development at Bayer

Bristol-Myers Squibb identifies Factor VIIa inhibitors

Promising data revealed on rindopipemut for the treatment of relapsed glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...